Financial Highlights Full Year 2012(1) Product sales $4,407 million +12% Product sales excluding ADDERALL XR $3,978 million +16% Total revenues $4,681 million +10% Non GAAP operating income $1,474 million +9% US GAAP operating income $949 million -14% Non GAAP diluted earnings per ADS $6.10 +14% US GAAP diluted earnings per ADS $3.93 -13% Non GAAP cash generation $1,637 million +18% Non GAAP free cash flow $1,256 million +43% US GAAP net cash provided by operating activities $1,383 million +29% (1) Percentages compare to the full financial year 2011.
Shire Delivers Strong 2012 Results And Reiterates Confidence In 2013
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.